Follicular Lymphoma
📧 Sign up to get email alerts when something new happens for Follicular Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2014-04-01Clinical Trial Update: An Efficacy and Tolerability Study of Bortezomib in Combination With Rituximab Standard Therapy in Participants With Relapsed or Refractory Follicular Lymphoma [Phase 2]
Phase 2 trial evaluating the combination of bortezomib and rituximab for relapsed or refractory follicular lymphoma was terminated.
-
CLINICAL_TRIALS trial_result · 2014-03-20Clinical Trial Update: A Study of SGN-40 in Combination With Rituximab in Patients With CD20-Positive, Follicular and Marginal Zone B-Cell Non-Hodgkin's Lymphoma [Phase 1]
Phase 1 study evaluating SGN-40 in combination with Rituximab in CD20-positive follicular and marginal zone B-cell non-Hodgkin's lymphoma ha…
-
CLINICAL_TRIALS trial_result · 2014-02-27Clinical Trial Update: Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma [Phase 2]
This update reports results from a Phase 2 trial of ixabepilone in relapsed or refractory aggressive non-Hodgkin lymphoma across multiple su…
-
CLINICAL_TRIALS trial_result · 2014-02-24Clinical Trial Update: Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas [Phase 1]
Phase 1 trial evaluating the combination of tanespimycin and bortezomib in adults with advanced solid tumors or lymphomas; the study was ter…
-
CLINICAL_TRIALS trial_result · 2014-02-11Clinical Trial Update: CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia [Phase 2]
A Phase 2 clinical trial evaluating CCI-779 (temsirolimus) in patients with recurrent or refractory B-cell non-Hodgkin lymphoma or chronic l…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2014-01-30Clinical Trial Update: Autologous Vaccine for Follicular Lymphoma [Phase 1]
This clinical trial update notes the completion of a Phase 1 study of an autologous vaccine for follicular lymphoma sponsored by Icon Geneti…
-
CLINICAL_TRIALS trial_result · 2013-12-16Clinical Trial Update: Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma [Phase 1]
Phase 1 trial of a geldanamycin analogue in patients with advanced solid tumors or Non-Hodgkin lymphoma has been terminated.
-
CLINICAL_TRIALS trial_result · 2013-12-04Clinical Trial Update: Efficacy and Safety Study of Oral Fludarabine Phosphate in Combination With Mitoxantrone as First Line Treatment in Follicular NHL [Phase 2]
Phase 2 study evaluating the efficacy and safety of combining oral fludarabine phosphate with mitoxantrone as first-line therapy for follicu…
-
CLINICAL_TRIALS trial_result · 2013-09-30Clinical Trial Update: 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma [Phase 1]
Phase 1 trial evaluating Triapine (3-AP) in combination with gemcitabine in patients with advanced solid tumors or lymphoma has completed. I…
-
CLINICAL_TRIALS trial_result · 2013-09-30Clinical Trial Update: Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia [Phase 1]
Phase 1 trial evaluating bortezomib and fludarabine with or without rituximab in relapsed or refractory indolent non-Hodgkin lymphoma or chr…
-
CLINICAL_TRIALS research · 2013-09-17Clinical Trial Update: Chlorambucil Compared With Radiation Therapy in Treating Patients With Previously Untreated Stage III or Stage IV Follicular Lymphoma [Phase 3]
Phase 3 clinical trial comparing chlorambucil with radiation therapy in previously untreated stage III or stage IV follicular lymphoma.
-
FDA approval · 2013-08-30FDA Approved: ZEVALIN — Supplemental Application (Acrotech Biopharma Inc)
The FDA approved a supplemental application for ZEVALIN (ibritumomab tiuxetan) submitted by Acrotech Biopharma Inc.
-
CLINICAL_TRIALS trial_result · 2013-08-26Clinical Trial Update: Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 trial evaluating rituximab with interleukin-12 in several B-cell non-Hodgkin lymphomas. The study status is completed.
-
CLINICAL_TRIALS research · 2013-08-23Clinical Trial Update: Trial of Rituximab, Bendamustine (RB) for Patients With Follicular Lymphoma Refractory or Relapsed After Treatment With R-chemotherapy in First Line [Phase 2]
This is a Phase 2 clinical trial update for Rituximab plus Bendamustine in follicular lymphoma patients who are refractory or relapsed after…
-
CLINICAL_TRIALS research · 2013-08-02Clinical Trial Update: GM-CSF, Rituximab, and Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Follicular Non-Hodgkin Lymphoma [Phase 2]
Clinical trial update of a Phase 2 study evaluating GM-CSF, Rituximab, and combination chemotherapy in patients with previously untreated ad…
-
CLINICAL_TRIALS research · 2013-08-02Clinical Trial Update: GM-CSF and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma [Phase 2]
This clinical trial update describes a Phase 2 study of GM-CSF with Rituximab in previously untreated follicular lymphoma.
-
CLINICAL_TRIALS trial_result · 2013-07-01Clinical Trial Update: FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's Lymphoma [Phase 2]
A terminated Phase 2 trial evaluated FR901228 alone or with Rituximab and Fludarabine in relapsed or refractory low-grade B-cell non-Hodgkin…
-
CLINICAL_TRIALS trial_result · 2013-06-06Clinical Trial Update: Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer [Phase 1]
Phase 1 trial evaluating rituximab in combination with interleukin-2 in various hematologic cancers has completed.
-
CLINICAL_TRIALS withdrawal · 2013-06-06Clinical Trial Update: Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating obatoclax mesylate in combination with rituximab and bendamustine hydrochloride for relapsed or refrac…
-
CLINICAL_TRIALS trial_result · 2013-06-04Clinical Trial Update: Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma [Phase 1]
Phase 1 study evaluating a combination of alvocidib, fludarabine phosphate, and rituximab in various B-cell lymphoproliferative disorders, w…
-
CLINICAL_TRIALS trial_result · 2013-06-04Clinical Trial Update: 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer [Phase 1]
Phase 1 clinical trial evaluating the combination of tanespimycin (17-allylamino-17-demethoxygeldanamycin) and bortezomib in relapsed or ref…
-
CLINICAL_TRIALS trial_result · 2013-05-16Clinical Trial Update: Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction [Phase 1]
This Phase 1 trial evaluated bortezomib in patients with advanced cancer and kidney dysfunction. The study has completed.
-
CLINICAL_TRIALS trial_result · 2013-05-16Clinical Trial Update: PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma [Phase 1]
A Phase 1 trial evaluating PXD101 in combination with 17-N-allylamino-17-demethoxygeldanamycin for metastatic or unresectable solid tumors o…
-
CLINICAL_TRIALS trial_result · 2013-05-03Clinical Trial Update: PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas [Phase 1]
A Phase 1 study evaluating belinostat (PXD101) in combination with bortezomib in adults with advanced solid tumors or lymphomas has complete…
-
CLINICAL_TRIALS trial_result · 2013-04-29Clinical Trial Update: Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma [Phase 2]
A Phase 2 study evaluated Velcade (bortezomib) in patients with relapsed follicular lymphoma; the trial completed and results were posted in…